

Form PTO-1595  
(Rev. 10/02)RECORDATION FORM COVER SHEET  
PATENTS ONLYU.S. DEPARTMENT OF COMMERCE  
U.S. Patent and Trademark Office

OMB No. 0651-0027 (exp. 6/30/2005)

Tab settings ⇒ ⇒ ⇒ ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

## 1. Name of conveying party(ies):

DNA Sciences, Inc.

## 2. Name and address of receiving party(ies)

Name: Genaissance Pharmaceuticals, Inc.

Internal Address: \_\_\_\_\_

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

## 3. Nature of conveyance:

- ☒ Assignment ☐ Merger  
☐ Security Agreement ☐ Change of Name  
☐ Other \_\_\_\_\_

Street Address: Five Science ParkCity: New Haven State: CT Zip: 06511Execution Date: May 15, 2003Additional name(s) & address(es) attached? ☐ Yes ☒ No

## 4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

## A. Patent Application No.(s)

09/805,619; 09/861,081; 09/805,813; 60/378,451  
09/558,245; 09/861,078; 10/214,914; 60/369,961

## B. Patent No.(s)

6,458,544; 6,355,433

Additional numbers attached? ☒ Yes ☐ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Melodie W. HendersonInternal Address: Genaissance Pharmaceuticals, Inc.Street Address: Five Science ParkCity: New Haven State: CT Zip: 065116. Total number of applications and patents involved: 127. Total fee (37 CFR 3.41).....\$ 480.00

- ☐ Enclosed  
☒ Authorized to be charged to deposit account

## 8. Deposit account number:

50-1293

(Attach duplicate copy of this page if paying by deposit account)

## DO NOT USE THIS SPACE

## 9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*Sandra L. Shaner 47,934

Name of Person Signing

Sandra L. Shaner

Signature

10/21/03

Date

Total number of pages including cover sheet, attachments, and documents:

Mail documents to be recorded with required cover sheet information to:

Filed together with a new patent application to:

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Not filed with new patent application to:

Mail Stop Assignment Recordation Services  
Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

700049086

PATENT

REEL: 014059 FRAME: 0683

CH \$480.00 501293 09805619

**ATTACHMENT FOR RECORDATION FORM COVER SHEET  
PATENTS ONLY (Form PTO-1595)****1. Name of conveying party(ies):**

DNA Sciences, Inc.  
\_\_\_\_\_  
\_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Additional name(s) of conveying party(ies) attached?

☐ Yes ☒ No**2. Name and address of receiving party(ies)**Name: Genaissance Pharmaceuticals, Inc.

Internal Address: \_\_\_\_\_

Street Address: Five Science ParkCity: New Haven State: CT ZIP: 06511

Name and address of receiving party(ies)

Name: \_\_\_\_\_

Internal Address: \_\_\_\_\_

Street Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Additional name(s) &amp; address(es) attached?

☐ Yes ☒ No**4. Application number(s) or patent number(s):**

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

**A. Patent Application No.(s)**

60/412,092; 09/724,389  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**B. Patent No.(s)**

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Additional numbers attached?

☐ Yes ☒ No

Attorney Docket No:

PATENT

**ASSIGNMENT OF PATENT RIGHTS  
(Company to Company)**

DNA Sciences, Inc., a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 6540 Kaiser Dr., Fremont, California (herein referred to as "Assignor") owns the entire right, title and interest in any Letters Patent(s) ("said patent(s)") and any Patent application(s) ("said application(s)") set forth in Schedule 1 attached hereto, as well as any invention(s) ("said invention(s)") disclosed in said application(s) and said patent(s).

WHEREAS, Genaissance Pharmaceuticals, Inc., a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at Five Science Park, New Haven, Connecticut (herein referred to as "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), the entire right, title and interest in and to any and all causes of action for infringement of said application(s) and said patent(s), including, but not limited to the right to recover damages, including provisional or other royalties, for prior infringements of said application(s) and said patent(s), and the entire right, title, and interest in and to any Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s);

NOW, THEREFORE, in consideration of the purchase price set forth in Section 3.1 of that certain Asset Purchase Agreement by and between DNA Sciences, Inc. and Genaissance Pharmaceuticals, Inc. dated as of March 28, 2003, the receipt of which is hereby acknowledged, the Assignor has granted, sold, assigned, transferred, conveyed and delivered, and by these presents does grant, sell, assign, transfer, convey and deliver, unto the Assignee, its successors and legal representatives, and assigns the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), including divisions, continuations, and continuations-in-part of said application(s), the entire right, title and interest in and to any and all causes of action for infringement of said application(s) and said patent(s), including, but not limited to the right to recover damages, including provisional or other royalties, for prior infringements of said application(s) and said patent(s), the entire right, title and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s), the entire right, title and interest in and to any and all reissues and extensions of said patent(s), and all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall reasonably request in connection with said invention(s), said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said invention(s) or said application(s), including interference proceedings, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention(s), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the assignee of said invention(s) and the Letters Patent to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 15 May 03

By: [Signature]

Name: Steven Lehrer  
Title: President  
Company: DNA Sciences, Inc.

State of: California

County of: Alameda

The preceding Assignment was acknowledged before me this 15<sup>th</sup> day of May  
2003 by Steven Lehrer

[Signature]  
Notary Public

My Commission Expires: 9/10/03



**SCHEDULE 1****UNITED STATES PATENTS ISSUED AND PENDING**

1. US Patent No. 6,458,544; issued October 1, 2002. Methods For Determining Single Nucleotide Variations And Genotyping.
2. No. 09/805,619; filed March 13, 2001. A Method And System For Aggregating Persons With A Select Profile For Further Medical Characterization.
3. No. 09/558,245; filed April 25, 2000. Detection Of Nucleotide Sequence Variations Via The Proofreading Activities Of Polymerases.
4. No. 09/861,078; filed May 26, 2000. System For Genetically Characterizing An Individual For Evaluation Using Genetic And Phenotypic Variations Over A Wide Area Network
5. No. 09/861,081; filed May 18, 2001. Computer Program Product For Genetically Characterizing An Individual For Evaluation Using Genetic And Phenotypic Variations Over A Wide Area Network.
6. No. 10/214,914; filed August 7, 2002. Polymorphisms Associated With Multiple Sclerosis.
7. No. 10/224,683; filed August 20, 2002. Polymorphisms Associated With Ion-channel Genetic Pathways.
8. No. 60/369,961; filed April 3, 2002. Methods of Diagnosing Schizophrenia.
9. No. 60/378,451; filed May 3, 2002. Polymorphisms Associated With Inflammatory Bowel Disease.
10. No. 10/163,598; filed June 5, 2002. Method Of Identifying A Polymorphism In CYP2D6.
11. US Patent No. 5,714,329; issued February 3, 1998; assigned to DNA Sciences, Inc. January 14, 2002. Diagnosis Of A Genetic Predisposition To Cancer Associated With Variant CDK4 Allele.
12. US Patent No. 6,432,639; issued August 13, 2002. Genotyping Of Human CYP3A4.
13. No. 10/085,612; filed February 26, 2002. Methods For Evaluating The Ability To Metabolize Pharmaceuticals And Compositions Therefor.
14. US Patent No. 6,448,003; issued September 10, 2002. Genotyping The Human Phenol Sulfotransferase 2 Gene.
15. US Patent No. 6,479,236; issued November 12, 2002. Genotyping The Human UDP-Glucuronosyltransferase 1 (UGT1) Gene.

16. No. 09/356,806; filed July 20, 1999. Genotyping Human UDP-Glucuronosyl Transferase 2B4 (UGT2B4) 2B7 (UGT2B7) And 2B15 (UGT2B15) Genes.
17. US Patent No. 6,492,115; issued December 10, 2002. Genetic Typing Of The Human Cytochrome P450 2A6 Gene And Related Materials And Methods.
18. No. 09/724,389; filed November 28, 2000. Genetic Typing Of Human Genes And Related Materials And Methods.
19. US Patent No. 6,355,433; issued March 12, 2003. Determination of Nucleotide Sequence Variations Through Limited Primer Extension.
20. No. 09/805,813; filed March 13, 2001. Database System and Method.
21. No. 60/412,092; filed September 18, 2002. Genotyping the Human UDP - glucuronosyltransferase 1 (UGT1) Gene.
22. No. 10/247,159; filed September 18, 2002. Genotyping the Human UDP - Glucuronosyltransferase 1 (UGT1) Gene.
23. No. 10/232,634; filed August 30, 2002. Genotyping of the Human Cytochrome P450 2A6 Gene and Related Materials and Methods.